產品貨號

CP132

產品規格

1/5/25/50/100mg

反應種屬

Mouse

克隆號

DC101-CP132

同種型

Mouse IgG2a(switched from rat IgG1)

免疫原

Mouse VEGFR-2-SEAPs soluble receptor

實驗應用

in vivo blocking of VEGF/VEGFR-2 signaling*
in vitro blocking of VEGFR signaling*
Western blot*
*Reported for the original rat IgG1 DC101 antibody

產品形式

PBS, pH 7.0,Contains no stabilizers or preservatives

純度

>95%, Determined by SDS-PAGE

聚合

<5%, Determined by SEC

無菌處理

0.2 µm filtration

純化方式

Protein G

分子量

150 kDa

小鼠病原檢測

Ectromelia/Mousepox Virus: Negative

Hantavirus: Negative

K Virus: Negative

Lactate Dehydrogenase-Elevating Virus: Negative

Lymphocytic Choriomeningitis virus: Negative

Mouse Adenovirus: Negative

Mouse Cytomegalovirus: Negative

Mouse Hepatitis Virus: Negative

Mouse Minute Virus: Negative

Mouse Norovirus: Negative

Mouse Parvovirus: Negative

Mouse Rotavirus: Negative

Mycoplasma Pulmonis: Negative

Pneumonia Virus of Mice: Negative

Polyoma Virus: Negative

Reovirus Screen: Negative

Sendai Virus: Negative

Theiler’s Murine Encephalomyelitis: Negative

保存條件

抗體原液保存在4°C，不能冷凍保存。

推薦同型對照

InVivoPlus mouse IgG2a isotype control, unknown specificity（貨號BP0085）

推薦抗體稀釋液

InVivoPure pH 7.0 Dilution Buffer（貨號IP0070）

體內VEGF/VEGFR-2信號阻斷

(in vivo blocking of VEGF/VEGFR-2 signaling)

1. Ding, X., et al. (2015). 'Distinct functions of epidermal and myeloid-derived VEGF-A in skin tumorigenesis mediated by HPV8' Cancer Res 75(2): 330-343.

2. Lee, H. J., et al. (2015). 'Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1alpha maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature' Int J Radiat Oncol Biol Phys 91(3): 621-630.

3. Arulanandam, R., et al. (2015). 'VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection' Cancer Cell 28(2): 210-224.

4. Kizhatil, K., et al. (2014). 'Schlemm’s canal is a unique vessel with a combination of blood vascular and lymphatic phenotypes that forms by a novel developmental process' PLoS Biol 12(7): e1001912.

體內VEGF/VEGFR-2信號阻斷，體外VEGFR信號阻斷

(in vivo blocking of VEGF/VEGFR-2 signaling, in vitro blocking of VEGFR signaling)

1.Larrayoz, M., et al. (2014). 'Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype' EMBO Mol Med 6(4): 539-550.